| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Collaboration revenue | 12,475 | 3,847 | 1,573 | 2,336 |
| Research and development | 154,948 | 138,125 | 99,490 | 77,197 |
| General and administrative | 46,333 | 36,864 | 33,600 | 23,273 |
| Total operating expenses | 201,281 | 174,989 | 133,090 | 100,470 |
| Loss from operations | -188,806 | -171,142 | -131,517 | -98,134 |
| Interest income | 14,744 | 14,478 | 16,179 | 17,968 |
| Other expense | -380 | -651 | -435 | -232 |
| Total other income | 14,364 | 13,827 | 15,744 | 17,736 |
| Net loss | -174,442 | -157,315 | -115,773 | -80,398 |
| Net unrealized (losses) gains on marketable securities | -4 | -1,084 | -170 | 7,555 |
| Foreign currency translation adjustment | -5 | 96 | 34 | - |
| Comprehensive loss | -174,451 | -158,303 | -115,909 | -72,843 |
| Net loss per share, basic (in dollars per share) | -1.27 | -1.21 | -0.9 | -0.65 |
| Net loss per share, diluted (in dollars per share) | -1.27 | -1.21 | -0.9 | -0.65 |
| Weighted-average shares outstanding, basic (in shares) | 137,895,000 | 129,622,000 | 129,232,000 | 123,375,000 |
| Weighted-average shares outstanding, diluted (in shares) | 137,895,000 | 129,622,000 | 129,232,000 | 123,375,000 |
Avidity Biosciences, Inc. (RNA)
Avidity Biosciences, Inc. (RNA)